China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

Beigene Ltd China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer (Businesswire) 2022-06-10 13:00 BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC).
“NPC is one of the most common head and neck cancers in China and many parts of Asia. Treatment options have been …

Read the source article at Välkommen till Avanza
2022-06-10 15:00:00